Cardiotoxicity of Cancer Therapies: A Review for the Oncology Provider - SPOC
Brian Colwell Jensen, MD, will review the potential cardiotoxicity associated with radiation therapy, chemotherapy, and newer targeted cancer therapies.
These courses are intended for medical, radiation, and surgical oncologists, hematologists, advanced practice nurses, registered nurses, physician assistants, radiologic technologists, researchers, pharmacists, trainees, allied health personnel, and others who are interested in care for patients and survivors in North Carolina.
- Understand that receiving radiation therapy to the chest wall increases the likelihood of subsequently developing cardiovascular disease.
- Know that anthracycline-induced cardiotoxicity still occurs with contemporary dosing regimens and may lead to heart failure.
- Recognize that molecularly targeted cancer therapies, including HER2 antagonists, kinase inhibitors, and immune checkpoint inhibitors are associated with an array of cardiovascular complications.
Taking the Course
To continue, click the button Take Course.
If you do not see the button, please ensure that you are logged in. If you are logged in and still don't see the button, please contact us at firstname.lastname@example.org or (919) 445–1000.
Brian Colwell Jensen, MD
Associate Professor of Medicine
This Non-Credit Course does not have accreditation. It only offers general participation certificates.
- 1.00 Participation